Table 1.
Demographic and laboratory patient information.
| Patient | Days Since Symptom Onset | Age | Sex | Relevant Pre-Existing Medical Conditions | Relevant Medication | CRP [mg/L] | IL-6 [ng/L] | Serum Ferritin [µg/L] | Oxygen Demand * | Lowest SpO2 [%] |
|---|---|---|---|---|---|---|---|---|---|---|
| C19-01 | 9 | 61 | m | None | Ampicillin/sulbactam, Piperacillin/tazobactam, Levofloxacin | 58 | n/a | n/a | – | 89 |
| C19-02 | 8 | 51 | m | None | None | 53 | 40.2 | 501 | – | 95 |
| C19-03 | 6 | 78 | m | COPD GOLD 2B, Coronary heart disease, hypertension | Ampicillin/sulbactam | 97 | 63.3 | 1096 | 2 L/min | 82 |
| C19-04 | 13 | 58 | m | None | Ampicillin/sulbactam, Piperacillin/tazobactam, meropenem | 21 | 21 | 1140 | 6 L/min | 75 |
| C19-05 | 5 | 58 | m | None | None | 108 | 38.3 | 316 | – | 95 |
| C19-06 | 12 | 49 | m | NSCLC, Hodgkin’s disease 1991 (CR) | Hydroxychloroquine, azithromycin, cisplatin, paclitaxel, pembrolizumab (03/2020) | 33 | 9.1 | 155 | 3 L/min | 93 |
| C19-07 | 10 | 75 | m | Myocardial infarction (2004), urothelial carcinoma | None | 56 | 335 | 564 | – | 95 |
| C19-08 | 12 | 50 | m | Asthma | None | 12 | 1.9 | 280 | 2 L/min | 95 |
| C19-09 | 11 | 63 | m | Asthma, type 2 diabetes | None | 133 | 125 | 1068 | 4 L/min | 84 |
| C19-10 | 9 | 46 | m | Hypertension | None | 8 | 5.4 | n/a | – | 94 |
| C19-11 | 20 | 39 | m | None | Ampicillin/sulbactam | 46 | 4.7 | 249 | – | 94 |
| C19-12 | 20 | 53 | m | Type 2 diabetes | None | 7 | 1.5 | 526 | – | – |
| C19-13 | 14 | 44 | w | Multiple sclerosis, Breast cancer (2010) | Rituximab (last dose: 01/2020) | 33 | 371.9 | 292,7 | – | 94 |
| C19-14 | 10 | 56 | w | None | Hydroxychloroquine | 38 | 19.9 | 16,7 | – | 93 |
Abbreviations: COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; IL-6: interleukin-6; NSCLC: non-small-cell lung carcinoma. * nasal oxygen supply.